Figure 3From: A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)Proportion of subjects with HIV-1 RNA <50 copies/mL by baseline HIV-1 RNA at Week 48. Analyses include switch equal to failure (top) and switch not equal to failure (bottom).Back to article page